Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2004 Aug;242(8):710-6.
doi: 10.1007/s00417-004-0976-x. Epub 2004 Aug 10.

Keypathophysiologic pathways in age-related macular disease

Affiliations
Review

Keypathophysiologic pathways in age-related macular disease

Felix Roth et al. Graefes Arch Clin Exp Ophthalmol. 2004 Aug.

Abstract

Purpose: To review current knowledge of key pathogenetic pathways in age-related macular disease (AMD).

Methods: Experimental evidence and clinical observations are reviewed.

Results: A number of common downstream pathophysiologic pathways appear to be relevant in AMD manifestations irrespective of primary heterogeneous etiologies. These include sequelae of oxidative damage, retinal pigment epithelium (RPE) cell dysfunction with accumulation of lipofuscin and impairment of lysosomal functions, deposition of subsequently incompletely degraded material at the basal RPE cell side and alterations in Bruch's membrane extracellular matrix, immunologic responses to extracellular material (drusen) with subsequent growth of drusen, induction of choroidal neovascularization as a result of imbalance between anti-angiogenetic and proangiogenetic factors as well as cell death (geographic atrophy) without prior neovascular events.

Conclusions: Understanding is expanding regarding the sequence of events that lead to early and late lesions in AMD. Therapeutic approaches that focus on the molecular mechanisms are more likely to succeed than currently available treatment options as exemplified by the management of choroidal neovascularisations.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br J Ophthalmol. 2000 Jul;84(7):741-5 - PubMed
    1. Invest Ophthalmol Vis Sci. 1994 Jan;35(1):64-77 - PubMed
    1. Am J Ophthalmol. 2001 Jun;131(6):767-81 - PubMed
    1. Eye (Lond). 1995;9 ( Pt 6):763-71 - PubMed
    1. Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34 - PubMed

LinkOut - more resources